The FDA recently approved the first new drug for Alzheimer's in the last 18 years. . Why are we not celebrating? Because there are a slew of concerns about the approval decision. Ten out of eleven members of an independent review board voted against approval. The eleventh couldn't decide. At least three of these reviewer have resigned in protest. In this podcast I review four of the main concerns about the FDA approval of Aduhelm.